Indaptus Therapeutics Inc (INDP)

$2.41 +0.13 (5.70%)
Market Cap 2.86M
Revenue (ttm) 0.00
Net Income (ttm) -15.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 363,625
Avg Vol 89,292
Day's Range N/A - N/A
Shares Out 1.11M
Stochastic %K 1%
Beta 1.27
Analysts Strong Sell
Price Target $25.00

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 427 2727
Address:
Three Columbus Circle, 15th Floor, New York, United States
Biomechanika
Biomechanika Sep. 16 at 11:45 AM
$INDP They better get it together for the next data publication or this company is screwed.
0 · Reply
RiZzBoTt
RiZzBoTt Sep. 16 at 3:51 AM
$INDP opened up a starter position here today. Looks bottomed out. LFG!
0 · Reply
RedDogSailor
RedDogSailor Sep. 15 at 4:13 PM
$INDP Insane
0 · Reply
Sam201
Sam201 Sep. 14 at 11:35 AM
$GNLN $INDP - tiny floats!!! 1million ish! Opposite holds by non-affiliates ( Gnln mostly non affiliates while indp mostly by institutions/insiders). N very high borrowing percentage. We saw some squeeze Friday AH. Both can jump really high before they dilute preexisting with S-3 (not effective yet in Gnln)! Keep an eye on $BON $BHAT , n $CDT too!
1 · Reply
Bullbear1010101
Bullbear1010101 Sep. 12 at 11:12 PM
$INDP barely any bounce since 3.6. might try small amount for monday but probably wont. maybe worse news???
0 · Reply
debbiekatz
debbiekatz Sep. 12 at 10:52 PM
$INDP posted at 2.49 today for team. hit 3.81 today for 53% gain on the daytrade. sold off and down to 2.39 now.
0 · Reply
CatchingBullets
CatchingBullets Sep. 12 at 10:01 PM
$CHEK $HUIZ $INDP $IHT MITQ Watchers growing here top play for next week!
0 · Reply
Frogsolf
Frogsolf Sep. 12 at 9:44 PM
$INDP Sell🙂‍↔️ BUY?🙂‍↕️ 321%??? Holly shxt let’s go!!!! 5$
1 · Reply
Reesifer
Reesifer Sep. 12 at 9:38 PM
$INDP added 2.37
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 12 at 9:31 PM
$INDP wow lower lows
0 · Reply
Latest News on INDP
Indaptus Therapeutics Provides Clinical Update

Sep 4, 2025, 4:01 PM EDT - 12 days ago

Indaptus Therapeutics Provides Clinical Update

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 14 days ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 8:00 AM EDT - 4 weeks ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jul 1, 2025, 8:14 AM EDT - 2 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Announces Reverse Stock Split

Jun 25, 2025, 7:00 AM EDT - 2 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 13, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 8:00 AM EDT - 4 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 8:00 AM EDT - 4 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 20, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 18, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 7:30 AM EDT - 6 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 6 months ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Mar 4, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 25, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Feb 5, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Jan 8, 2025, 8:00 AM EST - 8 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 22, 2024, 8:36 AM EST - 10 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 11, 2024, 8:00 AM EST - 11 months ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Nov 7, 2024, 8:00 AM EST - 11 months ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Oct 23, 2024, 8:00 AM EDT - 11 months ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Jan 4, 2024, 8:00 AM EST - 1 year ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Feb 14, 2023, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Dec 13, 2022, 7:30 AM EST - 3 years ago

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Biomechanika
Biomechanika Sep. 16 at 11:45 AM
$INDP They better get it together for the next data publication or this company is screwed.
0 · Reply
RiZzBoTt
RiZzBoTt Sep. 16 at 3:51 AM
$INDP opened up a starter position here today. Looks bottomed out. LFG!
0 · Reply
RedDogSailor
RedDogSailor Sep. 15 at 4:13 PM
$INDP Insane
0 · Reply
Sam201
Sam201 Sep. 14 at 11:35 AM
$GNLN $INDP - tiny floats!!! 1million ish! Opposite holds by non-affiliates ( Gnln mostly non affiliates while indp mostly by institutions/insiders). N very high borrowing percentage. We saw some squeeze Friday AH. Both can jump really high before they dilute preexisting with S-3 (not effective yet in Gnln)! Keep an eye on $BON $BHAT , n $CDT too!
1 · Reply
Bullbear1010101
Bullbear1010101 Sep. 12 at 11:12 PM
$INDP barely any bounce since 3.6. might try small amount for monday but probably wont. maybe worse news???
0 · Reply
debbiekatz
debbiekatz Sep. 12 at 10:52 PM
$INDP posted at 2.49 today for team. hit 3.81 today for 53% gain on the daytrade. sold off and down to 2.39 now.
0 · Reply
CatchingBullets
CatchingBullets Sep. 12 at 10:01 PM
$CHEK $HUIZ $INDP $IHT MITQ Watchers growing here top play for next week!
0 · Reply
Frogsolf
Frogsolf Sep. 12 at 9:44 PM
$INDP Sell🙂‍↔️ BUY?🙂‍↕️ 321%??? Holly shxt let’s go!!!! 5$
1 · Reply
Reesifer
Reesifer Sep. 12 at 9:38 PM
$INDP added 2.37
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 12 at 9:31 PM
$INDP wow lower lows
0 · Reply
warrenjunior
warrenjunior Sep. 12 at 9:28 PM
$INDP
0 · Reply
warrenjunior
warrenjunior Sep. 12 at 9:28 PM
$INDP It’s an opportunity I won’t miss, and I won’t even bother watching the volume because the daily timeframe is already heavily oversold. Inevitably, where else could it go? Next week should bring a solid wave of profit-taking.
0 · Reply
Frogsolf
Frogsolf Sep. 12 at 9:28 PM
$INDP 😜i buy
0 · Reply
MomentumDetector
MomentumDetector Sep. 12 at 9:27 PM
$TWLO $UAL $INDP $CYCU )
0 · Reply
Vampireslayers
Vampireslayers Sep. 12 at 9:16 PM
$MITQ $CHEK $INDP $UK $RETO top runners ah.
1 · Reply
RedDogSailor
RedDogSailor Sep. 12 at 9:10 PM
$INDP is about to explode. Decoy works and that spike was panicked shorts covering. I’m tripling down. And btw: I’m shorting the F out of $TSLA
1 · Reply
Sam201
Sam201 Sep. 12 at 8:58 PM
$INDP n loading back some!
0 · Reply
CatchingBullets
CatchingBullets Sep. 12 at 8:56 PM
$CHEK $HUIZ $INDP $CWD MITQ got all the eyes right now. Its going to squeeze, Holding full for next week.
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 12 at 8:52 PM
$INDP out 2.48 from 2.45
0 · Reply
topstockalerts
topstockalerts Sep. 12 at 8:50 PM
After Hours Top Gainers PT2 $ADAP $INDP $XHG $ASST $TLIH
0 · Reply
PrimeTimeHour
PrimeTimeHour Sep. 12 at 8:49 PM
$MITQ This is looking better and better. Bought more today. Imagine next week when more ppl finds this!! $CHECK $INDP $ATCH $ZKIN
0 · Reply
WavyTraders
WavyTraders Sep. 12 at 8:44 PM
Looks like ALL volume and momentum are shifting in to CMCT! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could pull a huge multi day run - only 700k float! Don't miss CMCT..,it's breaking out! $CXAI $FFAI $INDP $YGMZ m
0 · Reply